Tick Borne Encephalitis Market

ID: MRFR/HC/29268-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026
Tick Borne Encephalitis Market Research Report By Product Type (Tick-Borne Encephalitis (TBE) Vaccines, Tick Repellents, Diagnostic Tests, Antiviral Drugs), By Distribution Channel (Hospitals and Clinics, Pharmacies and Drug Stores, Online Marketplaces, Government Agencies), By End User (Travelers, Outdoor Enthusiasts, Healthcare Providers, Research Institutions), By TBE Vaccine Type (Inactivated TBE Viruses, Live Attenuated TBE Viruses, Subunit TBE Vaccines, DNA-Based TBE Vaccines) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Tick Borne Encephalitis Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.33%
2024 Market Size$ 10.86 Billion
2025 Market Size$ 11.65 Billion
2035 Market Size$ 23.64 Billion
Key Players
Bavarian Nordic
Valneva SE
Pfizer Inc.
Sanofi S.A.
GSK plc
Merck & Co.
Trends
  • Rising Awareness and Education
  • Advancements in Vaccine Development
  • Integration of Digital Health Solutions
Opportunities
  • Government Initiatives and Funding
  • Rising Travel and Outdoor Activities
  • Growing Research and Development Efforts
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Type (USD Billion)
      1. 4.1.1 Tick-Borne Encephalitis (TBE) Vaccines
      2. 4.1.2 Tick Repellents
      3. 4.1.3 Diagnostic Tests
      4. 4.1.4 Antiviral Drugs
    2. 4.2 Healthcare, BY Distribution Channel (USD Billion)
      1. 4.2.1 Hospitals and Clinics
      2. 4.2.2 Pharmacies and Drug Stores
      3. 4.2.3 Online Marketplaces
      4. 4.2.4 Government Agencies
    3. 4.3 Healthcare, BY End User (USD Billion)
      1. 4.3.1 Travelers
      2. 4.3.2 Outdoor Enthusiasts
      3. 4.3.3 Healthcare Providers
      4. 4.3.4 Research Institutions
    4. 4.4 Healthcare, BY TBE Vaccine Type (USD Billion)
      1. 4.4.1 Inactivated TBE Viruses
      2. 4.4.2 Live Attenuated TBE Viruses
      3. 4.4.3 Subunit TBE Vaccines
      4. 4.4.4 DNA-Based TBE Vaccines
    5. 4.5 Healthcare, BY Region (USD Billion)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bavarian Nordic (DK)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Valneva SE (FR)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer Inc. (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi S.A. (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 GSK plc (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck & Co., Inc. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Takeda Pharmaceutical Company Limited (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AbbVie Inc. (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TYPE
    4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 US MARKET ANALYSIS BY TBE VACCINE TYPE
    7. 6.7 CANADA MARKET ANALYSIS BY TYPE
    8. 6.8 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    9. 6.9 CANADA MARKET ANALYSIS BY END USER
    10. 6.10 CANADA MARKET ANALYSIS BY TBE VACCINE TYPE
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY TYPE
    13. 6.13 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    14. 6.14 GERMANY MARKET ANALYSIS BY END USER
    15. 6.15 GERMANY MARKET ANALYSIS BY TBE VACCINE TYPE
    16. 6.16 UK MARKET ANALYSIS BY TYPE
    17. 6.17 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    18. 6.18 UK MARKET ANALYSIS BY END USER
    19. 6.19 UK MARKET ANALYSIS BY TBE VACCINE TYPE
    20. 6.20 FRANCE MARKET ANALYSIS BY TYPE
    21. 6.21 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    22. 6.22 FRANCE MARKET ANALYSIS BY END USER
    23. 6.23 FRANCE MARKET ANALYSIS BY TBE VACCINE TYPE
    24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE
    25. 6.25 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    26. 6.26 RUSSIA MARKET ANALYSIS BY END USER
    27. 6.27 RUSSIA MARKET ANALYSIS BY TBE VACCINE TYPE
    28. 6.28 ITALY MARKET ANALYSIS BY TYPE
    29. 6.29 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    30. 6.30 ITALY MARKET ANALYSIS BY END USER
    31. 6.31 ITALY MARKET ANALYSIS BY TBE VACCINE TYPE
    32. 6.32 SPAIN MARKET ANALYSIS BY TYPE
    33. 6.33 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    34. 6.34 SPAIN MARKET ANALYSIS BY END USER
    35. 6.35 SPAIN MARKET ANALYSIS BY TBE VACCINE TYPE
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TBE VACCINE TYPE
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY TYPE
    42. 6.42 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    43. 6.43 CHINA MARKET ANALYSIS BY END USER
    44. 6.44 CHINA MARKET ANALYSIS BY TBE VACCINE TYPE
    45. 6.45 INDIA MARKET ANALYSIS BY TYPE
    46. 6.46 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    47. 6.47 INDIA MARKET ANALYSIS BY END USER
    48. 6.48 INDIA MARKET ANALYSIS BY TBE VACCINE TYPE
    49. 6.49 JAPAN MARKET ANALYSIS BY TYPE
    50. 6.50 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    51. 6.51 JAPAN MARKET ANALYSIS BY END USER
    52. 6.52 JAPAN MARKET ANALYSIS BY TBE VACCINE TYPE
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TBE VACCINE TYPE
    57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
    58. 6.58 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    59. 6.59 MALAYSIA MARKET ANALYSIS BY END USER
    60. 6.60 MALAYSIA MARKET ANALYSIS BY TBE VACCINE TYPE
    61. 6.61 THAILAND MARKET ANALYSIS BY TYPE
    62. 6.62 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    63. 6.63 THAILAND MARKET ANALYSIS BY END USER
    64. 6.64 THAILAND MARKET ANALYSIS BY TBE VACCINE TYPE
    65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE
    66. 6.66 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    67. 6.67 INDONESIA MARKET ANALYSIS BY END USER
    68. 6.68 INDONESIA MARKET ANALYSIS BY TBE VACCINE TYPE
    69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
    70. 6.70 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    71. 6.71 REST OF APAC MARKET ANALYSIS BY END USER
    72. 6.72 REST OF APAC MARKET ANALYSIS BY TBE VACCINE TYPE
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE
    75. 6.75 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    76. 6.76 BRAZIL MARKET ANALYSIS BY END USER
    77. 6.77 BRAZIL MARKET ANALYSIS BY TBE VACCINE TYPE
    78. 6.78 MEXICO MARKET ANALYSIS BY TYPE
    79. 6.79 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    80. 6.80 MEXICO MARKET ANALYSIS BY END USER
    81. 6.81 MEXICO MARKET ANALYSIS BY TBE VACCINE TYPE
    82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
    83. 6.83 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    84. 6.84 ARGENTINA MARKET ANALYSIS BY END USER
    85. 6.85 ARGENTINA MARKET ANALYSIS BY TBE VACCINE TYPE
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TBE VACCINE TYPE
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TBE VACCINE TYPE
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TBE VACCINE TYPE
    99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
    100. 6.100 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    101. 6.101 REST OF MEA MARKET ANALYSIS BY END USER
    102. 6.102 REST OF MEA MARKET ANALYSIS BY TBE VACCINE TYPE
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    111. 6.111 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    113. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    115. 6.115 HEALTHCARE, BY TBE VACCINE TYPE, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY TBE VACCINE TYPE, 2024 TO 2035 (USD Billion)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.2.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.2.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.3.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.3.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.4.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.4.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.5.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.5.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.6.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.6.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.7.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.7.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.8.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.8.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.9.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.9.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.10.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.10.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.11.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.11.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.12.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.12.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.13.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.13.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.14.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.14.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.15.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.15.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.16.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.16.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.17.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.17.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.18.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.18.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.19.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.19.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.20.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.20.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.21.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.21.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.22.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.22.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.23.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.23.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.24.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.24.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.25.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.25.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.26.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.26.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.27.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.27.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.28.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.28.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.29.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.29.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
      3. 7.30.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.30.4 BY TBE VACCINE TYPE, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Tick Borne Encephalitis Market Segmentation

Tick Borne Encephalitis Market By Type (USD Billion, 2025-2035)

  • Tick-Borne Encephalitis (TBE) Vaccines
  • Tick Repellents
  • Diagnostic Tests
  • Antiviral Drugs

Tick Borne Encephalitis Market By Distribution Channel (USD Billion, 2025-2035)

  • Hospitals and Clinics
  • Pharmacies and Drug Stores
  • Online Marketplaces
  • Government Agencies

Tick Borne Encephalitis Market By End User (USD Billion, 2025-2035)

  • Travelers
  • Outdoor Enthusiasts
  • Tick Borne Encephalitis Market Providers
  • Research Institutions

Tick Borne Encephalitis Market By TBE Vaccine Type (USD Billion, 2025-2035)

  • Inactivated TBE Viruses
  • Live Attenuated TBE Viruses
  • Subunit TBE Vaccines
  • DNA-Based TBE Vaccines

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.